Recurrent GBM Stem Cell Tumor Amplified RNA Immunotherapy Trial is a PHASE1 clinical asset sponsored by John Sampson in Recurrent Central Nervous System Neoplasm. SEO and diligence focus: BTSC mRNA-loaded DCs, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.